Skip to content
CancerIndex

Publication

Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

Authors not recorded

Sci Transl Med2011PMID 22072639PMC3319004stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (5)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 5

Curated evidence

Evidence citing this paper (4)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
22072639
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
ALK F1174L2
CrizotinibNeuroblastomaPredictiveBSupports Resistance—rejected
EID2344

Activating mutations in the (ALK) gene are targeted by the dual-specific tyrosine kinase inhibitor crizotinib. The amino acid substitution F1174L resulted in a reduced response to crizotinib compared … (full text at CIViC)

PMID 22072639 · Bresler et al., 2011 · Open in CIViC

civic
〃NeuroblastomaPredictiveDSupports Resistance3accepted
EID125

Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation. The authors conclude that this effect should b… (full text at CIViC)

PMID 22072639 · Bresler et al., 2011 · Open in CIViC

civic
ALK R1275Q2
CrizotinibNeuroblastomaPredictiveBSupports Sensitivity Response—rejected
EID2341

Activating mutations in the (ALK) gene are targeted by the dual-specific tyrosine kinase inhibitor crizotinib. The amino acid substitution R1275Q resulted in an improved response to crizotinib.

PMID 22072639 · Bresler et al., 2011 · Open in CIViC

civic
〃NeuroblastomaPredictiveDSupports Sensitivity Response3accepted
EID143

Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation.

PMID 22072639 · Bresler et al., 2011 · Open in CIViC

civic